In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on GE Healthcare Technologies Inc, with a price target of $87.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Zimmerman has given his Buy rating due to a combination of factors influencing GE Healthcare Technologies Inc. One significant reason is the robust growth potential within the Pharmaceutical Diagnostics segment, which contributes significantly to the company’s revenue. The segment has shown impressive year-over-year growth, and future expectations remain optimistic with high single-digit growth anticipated.
Additionally, strategic partnerships, such as those with Cardiovascular Associates of America and CardioNavix, are expected to drive the adoption of Flyrcado, potentially unlocking a substantial revenue opportunity. Despite some competitive challenges, such as the introduction of a generic version of Omnipaque, GEHC’s valuation remains attractive. The company’s price target is set at $87, based on a multiple that reflects both improved execution and broader macroeconomic risks, positioning it favorably compared to its large-cap peers.